De Moel EC[au] - Search Results

Year	Number of Results
2017	1
2018	4
2019	3
2021	1
2023	1
2024	0

1

Geo-epidemiology of autoantibodies in rheumatoid arthritis: comparison between four ethnically diverse populations.

de Moel EC, Trouw LA, Terao C, Govind N, Tikly M, El-Gabalawy H, Smolik I, Bang H, Huizinga TWJ, Toes REM, van der Woude D. de Moel EC, et al. Arthritis Res Ther. 2023 Mar 8;25(1):37. doi: 10.1186/s13075-023-03009-7. Arthritis Res Ther. 2023. PMID: 36890568 Free PMC article.

2

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.

de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D. de Moel EC, et al. Cancer Immunol Res. 2019 Jan;7(1):6-11. doi: 10.1158/2326-6066.CIR-18-0245. Epub 2018 Nov 13. Cancer Immunol Res. 2019. PMID: 30425107

3

Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis.

Amkreutz JAMP, de Moel EC, Theander L, Willim M, Heimans L, Nilsson JÅ, Karlsson MK, Huizinga TWJ, Åkesson KE, Jacobsson LTH, Allaart CF, Turesson C, van der Woude D. Amkreutz JAMP, et al. Among authors: de moel ec. Arthritis Rheumatol. 2021 Jun;73(6):921-930. doi: 10.1002/art.41623. Epub 2021 May 10. Arthritis Rheumatol. 2021. PMID: 33314699 Free PMC article.

4

In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Goekoop-Ruiterman YPM, Steup-Beekman GM, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D. de Moel EC, et al. Ann Rheum Dis. 2018 Dec;77(12):1836-1838. doi: 10.1136/annrheumdis-2018-213823. Epub 2018 Jul 25. Ann Rheum Dis. 2018. PMID: 30045852 No abstract available.

5

Is optimising gout treatment the key to closing the mortality gap in gout patients?

Ten Brinck RM, de Moel EC, van der Pol JA, van Beest S, de Koning A, Huizinga TWJ. Ten Brinck RM, et al. Among authors: de moel ec. Ann Rheum Dis. 2018 Jan;77(1):e2. doi: 10.1136/annrheumdis-2017-211638. Epub 2017 May 25. Ann Rheum Dis. 2018. PMID: 28546256 No abstract available.

6

In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Collée G, Lard LR, Ramiro S, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D. de Moel EC, et al. Arthritis Res Ther. 2019 Jan 18;21(1):28. doi: 10.1186/s13075-019-1815-0. Arthritis Res Ther. 2019. PMID: 30658699 Free PMC article. Clinical Trial.

7

Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.

de Moel EC, Derksen VFAM, Stoeken G, Trouw LA, Bang H, Goekoop RJ, Speyer I, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D. de Moel EC, et al. Arthritis Res Ther. 2018 Feb 26;20(1):33. doi: 10.1186/s13075-018-1520-4. Arthritis Res Ther. 2018. PMID: 29482627 Free PMC article. Clinical Trial.

8

Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.

de Moel EC, Rech J, Mahler M, Roth J, Vogl T, Schouffoer A, Goekoop RJ, Huizinga TWJ, Allaart CF, Toes REM, Schett G, van der Woude D. de Moel EC, et al. Arthritis Res Ther. 2019 Dec 5;21(1):268. doi: 10.1186/s13075-019-2064-y. Arthritis Res Ther. 2019. PMID: 31805992 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year